ABSTRACT
INTRODUCTION
Alzheimer's disease is a progressive, neurodegenerative disease characterized in the brain by abnormal clumps (amyloid plaques) and tangled bundles of fibers (neurofibrillary tangles) composed of misplaced proteins. It manifests by a progressive decline in cognitive abilities such as memory, comprehension and language expression Mesenchymal stem cells (MSCs) are pluripotent cells isolated from the bone marrow and other various organs. They are able to proliferate and selfrenew, as well as to give rise to progeny of at least the osteogenic and adipogenic lineages (2).
In a previous work, it has been found that infusion of BM-derived MSCs either alone or associated with heme-oxygenase (HO) inducer exert a therapeutic effect against the brain lesion in Alzheimer's disease possibly through decreasing the brain cholesterol level and increasing seladin-1 gene expression
(3).
Curcumin (1,7bis (4 hydroxy-3 methoxy phenol)-1, 6 heptadiene-3, 5 dione) is a yellow phenolic compound present in turmeric (Curcuma-longa) a widely used spice in Indian cuisine. Curcumin has a number of biological applications along with a significant, anti-inflammatory antioxidant activity both invivo and invitro
(4).
Studies over the past three decades related to absorption, distribution, metabolism and excretion of curcumin have revealed poor absorption and rapid metabolism of curcumin that severely curtails its bioavailability (5). Because of the poor bioavailability of pure curcumin, a new water soluble curcumin derivative (Patent pending PCT/EG2010/000008) was used in this study.
This work aims to study the possible mechanisms of action of a water soluble curcumin derivative and MSCs in Alzheimer disease.
MATERIALS & METHODS

This work was performed at the Unit of Biochemistry and Molecular
Biology at The Medical Biochemistry Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
A novel water soluble curcumin derivative (NCD) was developed through covalent modification of the curcumin molecule on sites remote from its natural functional groups. The NCD was presented free of charge to the participating researchers as a personal non-profit scientific participation in the present study. 
Preparation of the animal model
Experimental animals
This study included seventy female rats obtained from an inbred strain of matched age and weight (6 months-1 year & 120-150gm). Animals were inbred in the Experimental Animal Unit, Faculty of Medicine, Cairo University. Rats were bred and maintained in an air conditioned animal house with specific pathogen free conditions, and were subjected to a 12:12-h daylight/darkness. Animals were fed a semi-purified diet that contained (gm/ 
C) Labeling of MSCs with PKH26
MSCs were harvested during the 4 th passage and were labeled with PKH26, which is a red fluorochrome. The fluorochrome has excitation (551 nm) and emission (567 nm) characteristics compatible with rhodamine or phycoerythrin detection systems.
The linkers are physiologically stable and show little to no toxic side-effects on cell systems. Labeled cells retain both biological and proliferating activity, and are ideal for in vitro cell labeling, in vitro proliferation studies and long, in vivo cell tracking. In the current work, MSCs were labeled with PKH26 from Sigma Company (St. Louis, MO/USA). Cells were centrifuged and washed twice in serum free medium. Cells were pelleted and suspended in dye solution. Cells were injected intravenously into rat tail vein. After one month, brain tissue was examined with a fluorescence microscope to detect and trace the cells.
II -QRT PCR for Bax, bcl2 and Seladin-1 gene expression in brain tissue:
Total RNA was extracted from brain tissue homogenate using RNeasy purification reagent (Qiagen, Valencia, CA). cDNA was generated from 5 μg of total RNA extracted with 1 μl (20 pmol) antisense primer and 0.8 μl superscript AMV reverse transcriptase for 60 min at 37 °C.
The relative abundance of mRNA species was assessed on an ABI prism 7500 sequence detector system (Applied Biosystems, Foster City, CA). PCR primers were designed with Gene Runner Software (Hasting Software, Inc., Hasting, NY) from RNA sequences from GenBank ( Table  1 ). All primer sets had a calculated annealing temperature of 60°. Quantitative RT-PCR was performed in duplicate in a 25-μl reaction volume consisting of 2X SYBR Green PCR Master Mix (Applied Biosystems), 900 nM of each primer and 2-3 μl of cDNA. Amplification conditions were 2 min at 50°, 10 min at 95° and 40 cycles of denaturation for 15 s and annealing/extension at 60° for 10 min. Data from real-time assays were calculated using the v1·7 Sequence Detection Software from PE Biosystems (Foster City, CA). Relative expression of Bax, bcl 2 , and seladin-1 mRNA was calculated using the comparative Ct method as previously described. All values were normalized to the -actin gene and reported as fold change over background levels detected in Alzheimer Disease. .
IV-Histopathological examination of brain tissues
Autopsy samples were taken from the brain of rats in different groups and fixed in 10% formol saline for twenty four hours. Washing was done in tap water then serial dilutions of alcohol (methyl, ethyl and absolute ethyl) were used for dehydration. Specimens were cleared in xylene and embedded in paraffin at 56 degree in hot air oven for twenty four hours. Paraffin bees wax tissue blocks were prepared for sectioning at 4 microns thickness by slidge microtome. The obtained tissue sections were collected on glass slides, deparaffinized, stained by hematoxylin &eosin stain for routine examination then examination was done through the light electric microscope (14) .
Statistical analysis
Data were coded and entered using the statistical package SPSS version 16. Data was presented as mean ± standard deviation. Comparisons between groups were done using analysis of variance (ANOVA) with multiple comparisons post hoc test in normally distributed quantitative variables while non para metrical kruscal-wallis test and mann-whitney test were used for non-normally distributed quantitative variables. Pvalues less than 0.05 were considered statistically significant. Values not sharing a common superscript differ significantly (p < 0.05). 
III-Estimation of MDA and GSH by colorimetry (Figure 4)
DISCUSSION
Alzheimer's disease (AD) is a neurodegenerative disease that leads to atrophy throughout the brain including the basal forebrain cholinergic system, amygdala, hippocampus and several other cortical areas. β-amyloid plaques and tau neurofibrillary tangles are hallmark features of AD . Curcumin may be a promising therapy for AD because it has different neuroprotective activities, including antioxidant, antiinflammatory and antiamyloidogenic properties (17) . One of the reasons suggested for the lack of beneficial results of curcumin in AD clinical trials has been the inability to produce sufficient brain levels following oral absorption (18) . It has been repeatedly shown that curcumin has poor water solubility and poor oral bioavailability, and that much of an administered dose is excreted in the feces (19, 5) . For this reason, we used in our study a novel curcumin derivative (NCD) to improve the bioavailability and delivery of curcumin.
In the present study, we aimed to evaluate the possible mechanisms of action of a novel curcumin derivative and MSCs in Alzheimer disease.
The pathophysiology of AD has not been clarified, but increasing evidence indicates that the loss of neurons in AD can be partly attributed to apoptosis (20) . Bax and Bcl-2 are important apoptotic factors and are receiving increased attention from researchers (21, 22) . In the present study, the Bax gene expression was significantly increased and the Bcl 2 gene expression was significantly decreased in AD compared to the control group. Our results also coincide with the work of Kudo et al.
(23) who injected oligomeric Aβ into the mouse hippocampus to induce neuronal cell death in 20 days. They reported that the number of neurons containing the active form of Bax was dramatically increased by Aβ injection, while the level of Bcl 2 was significantly decreased.
Curcumin is safe and can be used to antagonize apoptosis, tumor growth, oxidation, inflammation and hyperlipemia
(24)
. In our study, oral administration of NCD and pure curcumin significantly decreased BAX expression in AD. In addition, NCD significantly decreased BAX expression in AD compared to pure curcumin. On the other hand, NCD significantly increased Bcl 2 expression in AD while, pure curcumin increased Bcl 2 expression in AD but this difference was not significant suggesting that the NCD was more effective. Our study agrees with Wang et al.
(25) who tested the effects of curcumin treatment on a rat model of Alzheimer's disease induced by betaamlyoid (Aβ1-40).The results showed that Bax expression was remarkably decreased and Bcl-2 expression was increased in the rat Alzheimer's disease model after curcumin treatment. Curcumin can significantly improve spatial learning and memory functions in rats with Aβ1-40-induced Alzheimer's disease by modulating Bax and Bcl-2 expression.
Our results reported that the concomitant injection of MSCs and oral administration of NCD to AD rats provided a more significant decrease in BAX and increase in Bcl 2 expression compared to the AD +NCD group. Meanwhile, the injection of MSCs followed 2 weeks later by NCD showed a significant decrease in BAX but a non significant increase in Bcl 2 .
In the present study . Curcumin has been demonstrated to have a strong antioxidant neuroprotective effects, scavenging ROS and neutralizing nitric-oxide-(NO-) based free radicals. The antioxidant activity of curcumin may be mediated through antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px). Curcumin has been shown to serve as an acceptor, reacting with glutathione (GSH) and thioredoxin. Depletion in cellular GSH levels is an important measure of oxidative stress, which is implicated in the pathogenesis of AD. A study on postmortem brain of AD patients has revealed decreased levels of GSH in some area of the brain. It was demonstrated that curcumin is able to replenish the intracellular GSH pool. It was reported that curcumin mediates the direct detoxification of reactive nitrogen species such as peroxynitrite, thus exerting an antioxidant activity (18) .
Our histopathological results agree with the work of Ebrahimi et Al. (33) who reported that upon transplantation into the brain, MSCs promote endogenous neuronal growth, decrease apoptosis, reduce levels of free radicals, encourage synaptic connection from damaged neurons and regulate inflammation. MSCs may encourage repair and new growth of neurons through providing neurotrophic factors (BDNF), which seems to be a significant aspect among the mechanisms of MSCs for the treatment of brain diseases.
Our results also agree with Lee et al.
(9) who strongly suggested that intracerebral BM-MSC transplantation not only reduces amyloid load and tau phosphorylation in the brain, but also prevents cognitive decline and memory impairment, this occurs by activation of an endogenous microglial population with an alternative phenotype that has neuroprotective effects.
Our work is in accordance with recent advances in a study of AD performed by Wang et al.
(25) who revealed that astrocytes (AS) are key factors in the early pathophysiological changes in AD. Glial fibrillary acidic protein (GFAP), a marker specific to AS, is markedly more manifest during morphological modifications and neural degeneration signature during the onset of AD. Several studies investigating the functionality of curcumin have shown that it not only inhibits amyloid sedimentation but also accelerates the disaggregation of amyloid plaque.
Conclusion: Administration of BM-derived MSCs either alone or with the NCD exerts a therapeutic effect on the brain lesion in Alzheimer's disease. This effect may be through the antioxidant and antiapoptotic action of both MSCs and curcumin.
